Clinical Trial Update: A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial of RO7123520 in moderately to severely active rheumatoid arthritis that terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• RO7123520

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 2 | Status: TERMINATED | Results posted: 2020-01-29